

Tocilizumab ORDER FORM



Diagnosis: Patient weight _____ kgs Height _____ inches	
<input type="checkbox"/> Giant cell arteritis	<input type="checkbox"/> Rheumatoid arthritis
<input type="checkbox"/> Kidney transplant, pretransplant desensitization	<input type="checkbox"/> Neuromyelitis optica
<input type="checkbox"/> Kidney transplant, antibody-mediated rejection	<input type="checkbox"/> Other: _____
LABS: 1. PPD or IGRA before start of therapy if none in past 12 months. Notify provider of positive results. 2. CBC with differential prior to therapy, 4 to 8 weeks after therapy and every 3 months 3. ALT/AST, alkaline phosphatase, and total bilirubin prior to therapy, every 4 to 8 weeks after therapy for the first 6 months and every 3 months thereafter 4. Lipid panel prior to therapy and 4 to 8 weeks after start of therapy. 5. Pregnancy test if between 14 and 50 years old with gestational potential.	
TREATMENT: <i>select one</i> <input type="checkbox"/> Tocilizumab-bavi (Tofidence) - RFGH preferred <input type="checkbox"/> Tocilizumab (Actemra)	
Dose: <input type="checkbox"/> 4 mg/kg <input type="checkbox"/> 6 mg/kg <input type="checkbox"/> 8 mg/kg Maximum dose: 800 mg or: _____	Frequency: <input type="checkbox"/> Every 4 weeks. <input type="checkbox"/> Every _____ weeks
NURSING 1. Assess patient prior to each treatment for signs of infection, demyelinating disorders, new onset abdominal symptoms, or recent vaccinations. 2. Hold treatment and notify provider if symptoms of uncontrolled serious infections or live vaccines administered within 4 weeks of starting therapy. 3. Provide FDA medication guide prior to first dose. 4. Vital signs pre and post infusion. Patient may be discharged if post-infusion vital signs are stable. 5. Educate patient about signs and symptoms of severe infections, CNS demyelinating disorders, and new onset abdominal symptoms.	
REQUIRED Prior Authorization Number: _____ <input type="checkbox"/> pending <input type="checkbox"/> Complete <input type="checkbox"/> not needed* *If not needed is chosen, date, time and name of person at health insurer who authorized. Date: _____ Time: _____ Name: _____	
Checklist for non-RFGH credentialed providers: <input type="checkbox"/> Provider to provider communication is required. If the patient has a Primary Care Provider at RFGH, please contact that PCP. Otherwise, call (207) 474-5121 and ask to speak to hospitalist. Contacted provider: _____ REQUIRED DOCUMENTATION attached: <input type="checkbox"/> H&P completed within last year. <input type="checkbox"/> Documentation supporting diagnosis and prior therapies for diagnosis. <input type="checkbox"/> Documentation of tuberculosis (TB) testing – PPD or IGRA testing. Date of negative test: _____ <input type="checkbox"/> Patient is brought up to date with all immunizations before starting therapy. <input type="checkbox"/> List of current medications and allergies.	
FAX completed order to Oncology at 207-858-2131	

Provider signature _____ Date _____ time _____

If not RFGH credentialed: Printed name _____ Phone # _____

RFGH Co-signature _____ Date _____ time _____

Printed name _____
Prep: 8/25

Label or
Patient name _____

dob _____ Patient phone # _____